autophagy suppression |
shRNA against ATG7
|
mice with OCI-AML3 cells |
Autophagy suppression prolongs survival after chemotherapy |
promoting leukemia |
[9] |
autophagy suppression |
Spautin-1 |
mice with OCI-AML3 cells |
Autophagy suppression prolongs survival after chemotherapy |
promoting leukemia |
[10] |
autophagy suppression |
atg5 or atg7-floxed |
mice with BM transplantation of BM cells transduced with MLL-ENL |
Autophagy suppression delays AML progression and decreases frequencies of leukemia initiating cells |
promoting leukemia |
[15] |
autophagy suppression |
shRNA against ATG5 or ATG7
|
umbilical cord blood CD34+ cells |
Autophagy suppression reduces the frequencies of hematopoietic stem cells and progenitor cells |
suppressing leukemogenesis |
[131] |
mitophagy suppression |
sqstm1−/−
|
mice with BM transplantation of ldMBM cells transduced with MN1 |
Loss of SQSTM1 restored leukemia development |
promoting leukemia |
[19] |
mitophagy suppression |
shRNA against FIS1
|
MOLM-13 and primary AML cells |
Absence of FIS1 attenuates self-renewal capacity of leukemia stem cells and induce myeloid differentiation |
promoting leukemia |
[14] |
mitophagy suppression |
Chloroquine, Lys05, and bafilomycin A1
|
MOLM-13 cells |
Targeting mitophagy contributes to enhanced anti-leukemic effects of autophagy inhibitors to AML cells under hypoxia |
promoting leukemia |
[20] |
CMA improvement |
LAMP2 expression plasmid |
OCI-AML2 cells |
Overexpression of LAMP2 restores sensitivity to chemotherapy and increase cell death |
suppressing leukemia |
[28] |
CMA improvement |
HSP90 inhibitor 17-AAG |
NB4 cells |
CMA degrades mutant TP53 under metabolic stress |
suppressing leukemia |
[30] |